Abstract: The present disclosure is directed to compositions including a microemulsion comprising a blend of lecithin, a co-surfactant, and a salt of an acidifier, an ester of an acidifier, or combinations thereof. Uses of the compositions are also disclosed.

Abstract: The invention relates to dyed particles of a bleach material that comprise a coating. The invention also relates to the use of the dyed particles in detergent compositions.

Abstract: Articles that include water-soluble films and household care composition, where the films include a polyvinyl alcohol (PVOH) resin blend and optionally one or more additional components such as plasticizers, fillers, surfactants, and other additives. The PVOH resin blend includes a PVOH copolymer including one or more types of anionic monomer units such as a PVOH terpolymer and a PVOH polymer such as another PVOH anionic copolymer or a partially or completely hydrolyzed PVOH homopolymer. When the PVOH copolymer and PVOH polymer are blended in particular proportions and/or selected with regard to various criteria related to physical and chemical film properties, the resulting water-soluble film formed from the PVOH resin blend exhibits substantially improved aqueous dissolution properties, tensile strength properties, and/or tensile modulus properties.

Abstract: A method for preparing ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. The method comprises nanolipidic vehicles in which ethanol-containing substances are encapsulated, said ethanol-containing nanolipidic vehicles can be combined with food products, desserts or beverage ingredients including those that are subsequently frozen. The food product, dessert or beverage can remain in a frozen state during consumption by an individual. A composition comprising ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages.

Abstract: A bioreactor container comprising has an at least locally flexible wall and at least one container opening. The wall of the bioreactor container has a fluid-tight inner sheet, and an at least locally fluid-permeable or structured outer sheet. A method for testing the integrity of the bioreactor container also is provided.

Abstract: A system for monitoring growth media within a controlled environment is provided and includes a well plate having a plate top and a plate side and defines at least one well cavity. The plate top includes a top opening and the plate side includes a side opening and the side opening is communicated with one of the at least one well cavity. The system includes a sensor assembly unit that includes a unit structure defining a reference material chamber containing a reference material, a sensor chamber having a chamber opening, and a base chamber. Additionally, the system includes a reference electrode communicated with the reference material and the base chamber. A media sensor is provided and is communicated with the chamber opening and a media sensor electrode communicated with the media sensor. The reference electrode and media sensor electrode are communicated with a processing device.

Abstract: A combined anaerobic digester system and gas-to-liquid system is disclosed. The anaerobic digester requires heat, and produces methane. The gas-to-liquid system produces heat, and converts methane to higher-value products, including methanol and formaldehyde. As such, the combination of the two systems results in significant savings in terms of capital and operating expenses. A process for producing bio-formaldehyde and bio-formalin from biogas is also disclosed.

Abstract: Methods of culturing mixotrophic microorganisms in a state of balanced gas composition are disclosed. Parameters of a culture of mixotrophic microorganisms may be controlled to reduce the requirements of externally supplied gases and optimize the production and consumption of gases within the culture by the phototrophic and heterotrophic metabolisms of the mixotrophic microorganisms.

Abstract: Disclosed herein are bioreactor systems and methods of utilizing said systems.

Abstract: A composition for producing a fiber, containing (A) a polymer compound containing a unit structure represented by the formula (1) and a unit structure represented by the formula (2), (B) a crosslinking agent, (C) an acid compound, and (D) a solvent wherein each symbol in the formulas (1) and (2) is as described in the DESCRIPTION.

Abstract: The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.

Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.

Abstract: The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.

Abstract: A method for producing hematopoietic stem cells and/or hematopoietic progenitor cells from pluripotent stem cells is described. The method includes a step of culturing pluripotent stem cells in the presence of IGF2. A method is described for selecting an induced pluripotent stem cell(s) having high capacity to differentiate into hematopoietic stem cells and/or hematopoietic progenitor cells, or into blood cells, based on the expression level(s) of one or more genes such as TRIM58, CTSF, FAM19A5, and TCERG1L genes, or on the DNA methylation state(s) of the TRIM58, CSMD1, and/or FAM19A5 gene(s).

Abstract: The invention provides methods, compositions, uses and kits relating to exosomes isolated from progenitor cells.

Abstract: The invention relates to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein the adenoviruses are generated in a production cell by: (a) expressing an adenoviral pIX polypeptide from a nucleic acid sequence encoding adenoviral pIX polypeptide under the control of at least a minimal endogenous pIX promoter and a heterologous promoter; and (b) expressing the elements necessary for the production and assembly of the adenoviruses, thereby increasing the yield of adenoviruses generated in the production cell in comparison to the yield in the absence of nucleic acid sequence encoding the adenoviral pIX polypeptide. Further, the invention relates to a method for constructing an adenovirus library, a production cell, and the use of an adenoviral pIX polypeptide for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region.

Abstract: The present invention relates to a novel bacteriophage ?CJ25 (KCCM11463P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic Escherichia coli (APEC) of birds by using the bacteriophage ?CJ25 (KCCM11463P) or the composition.

Abstract: The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.

Abstract: The present invention discloses a type II Pseudorabies virus attenuated strain and its preparation method and application. The attenuated strain of pseudorabies virus is gE/TK-double-deficient strain, which is named as PRV-HD/c strain of PRV dual-deletion strain, and the accession number is CGMCC No. 14325. The attenuated strain of the pseudorabies virus of the present invention is obtained from the newly isolated strain of pseudorabies virus type II after deletion of the gE and TK double genes and has reduced pathogenicity and strong immunogenicity and is inactivated by the attenuated strain of pseudorabies virus vaccines or live attenuated vaccines, which can provide effective immunity to PRV susceptible animals such as pigs and mice.

Abstract: Chimeric polypeptides comprising a dihydrotestosterone (DHT) reductase moiety, such as 3 alpha-hydroxysteroid dehydrogenase (3?-HSD), fused to a signal peptide moiety, polynucleotides encoding same, and compositions comprising at least one microorganism cell capable of secreting the chimeric polypeptide, are provided. Further provided are methods and kits for treating, preventing or ameliorating androgen-dependent disorders, including but not limited to androgenic alopecia.

Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.

Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof are provided that allow for nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having lower systematic error as compared to a reference polymerase. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered properties.

Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.

Abstract: To provide an improved ?-fructofuranosidase which is capable of efficiently producing kestose while inhibiting the production of nystose. This improved ?-fructofuranosidase comprises either: an amino acid sequence (a) obtained by introducing, into the amino acid sequence represented by SEQ ID NO: 2, an amino acid mutation i) in which the 85th glycine (G) from the N-terminal is substituted for a protein-constituting amino acid other than glycine (G), and/or an amino acid mutation ii) in which the 310th histidine (H) from the N-terminal is substituted for lysine (K), arginine (R), or tyrosine (Y); or an amino acid sequence (b) which exhibits ?-fructofuranosidase activity, and which comprises an amino acid sequence obtained by deleting, substituting, inserting, or adding one or more amino acids in (a) other than the amino acid into which the amino acid mutation has been introduced.

Abstract: Methods for regulating protein activity by fusing dimerization domains to target protein are provided. Chimeric proteins that include dimerization domains fused to target proteins for altering the activity of the target proteins are described. Engineered nucleic acids encoding chimeric proteins and hosts engineered to express engineered nucleic acids are also provided.

Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalized and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation from both bread and durum wheat, barley, rye and oat flour. In particular, the invention concerns the use of lactic acid bacteria selected and fungal enzymes for the gluten complete degradation (residual gluten concentration lower than 20 ppm) of cereal flours, which after detoxification can be used according to a standardized biotechnological protocol for the production of various gluten-free foods.

Abstract: A gene expression cassette capable of producing psicose at high yield with high stability, a GRAS (Generally recognized as safe) microorganism, a method of producing the enzyme by using the GRAS microorganism, and a method of producing the psicose by using the GRAS microorganism and enzyme are provided.

Abstract: There is provided a biocatalyst solvent which is capable of dissolving a biocatalyst in a liquid state while maintaining the activity of the biocatalyst at a high concentration from a low temperature to a high temperature, and is capable of storing the biocatalyst for a long time period; and a biocatalyst solution using the biocatalyst solvent.

Abstract: A method of producing nanobiocatalysts includes: suspending a support material in a liquid medium; functionalizing a surface of the support material by mixing the suspended support material with a functionalizer for a first predefined time at a first predefined temperature, wherein a first broth results; applying a protein directly in the first broth after the first predefined time; mixing the protein with the first broth and incubating the protein for a second predefined time at a second predefined temperature, wherein a second broth results; immobilizing the incubated protein onto the functionalized surface of the support material, wherein a third broth results; filtering the third broth; and gathering a retentate of the filtering. By directly processing the first and second broths allows for providing a continuous process and production of the nanobiocatalysts, which can be optimized regarding time, water, chemical and energy consumption. Also, problems related to thixotrophy can be minimized.

Abstract: There are provided a radiofrequency device for increasing amount of a bioactive substance in a plant cell and a plant cell culture method for increasing amount of useful intracellular secondary metabolites by using the radiofrequency device. The cell culture method of the present invention makes it possible to increase specific secondary metabolites such as daidzein, equol, and the like in a cell and thus can be used for development into various medicines, agricultural pesticides, spices, pigments, food additives, and cosmetics containing bioactive substances. Further, the cell culture method of the present invention improves conventional cell culture methods limitedly used for specific cells or specific metabolites for increasing amount of intracellular bioactive substances and thus can be widely applied to production of cells and secondary metabolites.

Abstract: A reagent delivery method includes placing a reagent delivery column including a plurality of reagent storage elements therein in a centrifugal device, coupling a breaching element to the housing, and rotating the centrifugal device to force the reagent storage elements toward the breaching element, breaching of the reagent storage elements releasing reagent therein and communicating the same to an external environment. A reagent delivery system includes a column having a housing, a plurality of reagent storage element sheets positioned in the housing or forming a stack, a plurality of breaching elements, and a microplate having a plurality of wells, the microplate coupled to the housing where each well corresponds or aligns with a breaching element and a reagent storage element. The system can be rotated in a centrifugal device to force the reagent storage element stacks toward the breaching elements.

Abstract: The invention relates to a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas guide RNA (gRNA) comprising a targeting domain that is complementary to human genomic Epidermal Growth Factor Receptor (EGFR) DNA, and a vector system including one or more packaged vector(s) including: (a) a first regulatory element operably linked to a gRNA, and (b) a second regulatory element operably linked to a nucleic acid encoding a Cas protein. Also disclosed are methods of altering a nucleic acid sequence encoding EGFR in a cell including contacting the cell with a vector system, methods of treating lung cancer, and methods of selectively inducing apoptosis in a cell including administering a gRNA to the cell.

Abstract: The present invention generally relates to systems and methods for producing nucleic acids. In some aspects, relatively large quantities of oligonucleotides can be produced, and in some cases, the oligonucleotides may have a variety of different sequences and/or lengths. For instance, a relatively small quantity of oligonucleotides may be amplified to produce a large amount of nucleotides. In one set of embodiments, oligonucleotides may be amplified using PCR, then transcribed to produce RNA. The RNA may then be reverse transcribed to produce DNA, and optionally, the RNA may be selectively degraded or removed, relative to the DNA. In one set of embodiments, the oligonucleotides may be chemically modified. These modifications may include, but are not limited, to the adding of fluorescent dyes or other signaling entities.

Abstract: This invention relates to the synthesis of nucleic acid-encoded chemical libraries using common adaptor sequences. Nucleic acid strands coupled to chemical moieties may be contacted with identifier oligonucleotides comprising coding sequences encoding the chemical moieties and an adaptor oligonucleotides, such that the adaptor oligonucleotide hybridizes to both the nucleic acid strands and the identifier oligonucleotides to allow ligation of the identifier oligonucleotides to the nucleic acid strands. The adaptor oligonucleotide is then removed. Nucleic acid-encoded chemical libraries, and methods of producing or screening such libraries are provided.

Abstract: Compositions and methods for performing a template-switching reaction are provided that may include reducing or eliminating concatemerization of the template-switching oligonucleotide (TSO). In some embodiments, the composition may comprise: a reverse transcriptase; a TSO that includes a recognition sequence for a site-specific double strand nucleic acid cleaving enzyme, wherein the TSO has at its 3? end at least one nucleotide capable of hybridizing to at least one or more non-templated nucleotides added to a templated cDNA strand by the reverse transcriptase; and a site-specific double strand nucleic acid cleaving enzyme that cleaves the TSO at the recognition sequence.

Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.

Abstract: The present invention relates to an avian influenza virus miRNA and the identification, detection and application thereof. In particular, a kind of specific microRNA, miR-HA-3p, is screened for the first time through detecting the microRNA expression levels in samples of animals with avian influenza. The experiments prove that the miR-HA-3p, as a microRNA marker, can be very effective in detecting avian influenza virus and avian influenza. Furthermore, inhibiting the function of miR-HA-3p can be very effective in relieving symptoms of avian influenza and treating avian influenza. The microRNA revealed in the present invention for the first time can be developed into a detection agent and a therapeutic agent as well as the corresponding kits for the detection and treatment of avian influenza (e.g., H5N1).

Abstract: Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency.

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.

Abstract: The present invention relates to small RNAs, inhibitors thereof, inhibitors of enzymes producing thereof, and their use to modulate the response of a cell to a DNA damaging event. The invention concerns also a method to detect the presence or quantify DNA damage.

Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.

Abstract: The present disclosure provides methods for identifying agents that are candidate agents for treating atopic dermatitis. The present disclosure provides methods for diagnosing atopic dermatitis. The present disclosure provides compositions and methods for treating atopic dermatitis.

Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.

Abstract: The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

Abstract: Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human amyloid beta protein. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.

Abstract: A method of introducing naked dsRNA into a seed is provided. The method comprising contacting the seed with the naked dsRNA under conditions which allow penetration of the dsRNA into the seed, thereby introducing the dsRNA into the seed.

Abstract: A method of introducing naked dsRNA into a seed is provided. The method comprising contacting the seed with the naked dsRNA under conditions which allow penetration of the dsRNA into the seed, thereby introducing the dsRNA into the seed.

Abstract: Provided are plants that express, or overexpress, a pPLAIII? protein. Constitutive or seed-specific expression of pPLAIII? protein in Arabidopsis increases seed oil content, the amount of C20 and C22 fatty acids, and the amount of C56, C58, and C60 triacylglycerols, effectively resulting in significantly higher oil yield per plant. Use of pPLAIII? is therefore an effective biotechnological tool to significantly increase plant yield, including oil, and the amount of high value long chain fatty acids in agricultural and horticultural crops, especially oilseed crops.